Leadership Overview
Revance Therapeutics has 6 executives leading key functions including strategy, operations, finance, human resources, revenue, and legal.
Driven by innovation, Revance Therapeutics is dedicated to advancing the science of neuromodulators for aesthetic and therapeutic applications, aiming to redefine patient care and outcomes through novel product development and commercialization.
Driven by innovation, Revance Therapeutics is dedicated to advancing the science of neuromodulators for aesthetic and therapeutic applications, aiming to redefine patient care and outcomes through novel product development and commercialization.
Leadership Roles at Revance Therapeutics
Nadeem Moiz - Chief Executive Officer
Nadeem Moiz, the Chief Executive Officer at Revance Therapeutics, directs the company's overarching strategy and vision, guiding the development and commercialization of novel botulinum toxin products. Moiz oversees the advancement of DaxibotulinumtoxinA for injection (RT002) through its critical Phase III clinical trials for aesthetic indications and Phase II trials for therapeutic conditions like cervical dystonia and plantar fasciitis. This leadership role involves steering the company's pipeline, including the preclinical development of DaxibotulinumtoxinA topical gel (RT001). Nadeem Moiz ensures alignment across all departments, fostering an environment of innovation essential for achieving the company's mission to redefine patient care. The Chief Executive Officer's focus remains on driving long-term growth and market leadership in the biotechnology sector, leveraging scientific expertise to deliver transformative solutions.
Scott Leffler - Chief Financial Officer
Scott Leffler, the Chief Financial Officer at Revance Therapeutics, directs all financial planning, reporting, and capital allocation strategies to support the company's growth and product development initiatives. Leffler oversees the financial health of the organization, managing budgets, forecasting, and investor relations to ensure sustainable funding for clinical trials and commercial expansion. This role involves rigorous financial oversight of the development pipeline, including DaxibotulinumtoxinA for injection (RT002) and the topical gel (RT001). The Chief Financial Officer ensures compliance with all financial regulations and drives strategies for maximizing shareholder value. Scott Leffler's financial acumen is critical in navigating the complex economic landscape of the biotechnology industry, securing resources for innovation and operational excellence.
Nicholas Crowe - Chief Operating Officer
Nicholas Crowe, the Chief Operating Officer at Revance Therapeutics, manages the day-to-day operational execution and scaling of the company's manufacturing and commercialization efforts. Crowe directs the complex processes involved in bringing novel botulinum toxin products from development to market, ensuring efficiency and quality across all operational facets. This involves overseeing the supply chain, manufacturing capabilities, and the logistical integration required for clinical trials and product launches. The Chief Operating Officer's responsibilities extend to optimizing internal workflows and ensuring robust infrastructure to support the company's growth trajectory. Nicholas Crowe plays a pivotal part in translating scientific advancements into tangible products, driving operational excellence to meet market demands and support the company's strategic objectives in the biotechnology landscape.
Matthew Argano - Chief Human Resources Officer
Matthew Argano, the Chief Human Resources Officer at Revance Therapeutics, leads the strategic development and implementation of all human capital initiatives, fostering a high-performance culture aligned with the company's mission. Argano oversees talent acquisition, employee development, compensation, and benefits programs, ensuring the organization attracts and retains top scientific and operational talent. This role is crucial for building and maintaining a skilled workforce capable of driving innovation in biotechnology. The Chief Human Resources Officer champions employee engagement and organizational effectiveness, supporting the company's ambitious goals for its novel botulinum toxin products. Matthew Argano's leadership ensures that Revance Therapeutics possesses the human capital necessary to achieve its scientific and commercial objectives.
Steven Kreider - Executive Vice President & Chief Revenue Officer, Aesthetics & Therapeutics
Steven Kreider, the Executive Vice President & Chief Revenue Officer, Aesthetics & Therapeutics at Revance Therapeutics, drives the commercial strategy and revenue generation for the company's aesthetic and therapeutic product lines. Kreider oversees all sales, marketing, and business development activities, focusing on maximizing market penetration for DaxibotulinumtoxinA for injection (RT002) and other pipeline assets. This leadership position involves building and managing high-performing commercial teams and forging strategic partnerships to expand market reach. The Executive Vice President & Chief Revenue Officer, Aesthetics & Therapeutics ensures that the company's innovative products effectively reach target patient populations and healthcare providers. Steven Kreider's expertise is instrumental in translating scientific breakthroughs into significant commercial success and revenue growth.
Kira Schwartz - Chief Legal Officer
Kira Schwartz, the Chief Legal Officer at Revance Therapeutics, provides strategic legal counsel and oversees all legal affairs, ensuring compliance and mitigating risk across the organization. Schwartz manages intellectual property, regulatory compliance, corporate governance, and litigation matters, safeguarding the company's assets and interests. This role is critical in navigating the complex regulatory landscape inherent in the biotechnology and pharmaceutical industries. The Chief Legal Officer ensures that all business activities, from product development to commercialization, adhere to legal and ethical standards. Kira Schwartz's legal expertise is essential for protecting the company's innovations, including its novel botulinum toxin products, and supporting its strategic objectives in the global market.
Explore Leadership Teams in Manufacturing
Unither Pharmaceuticals is a global contract development and manufacturing organization (CDMO) specializing in the production of single-dose liquid pharmaceuticals and sterile unit-dose formats for the pharmaceutical and consumer healthcare industries. The company is recognized as a world leader in blow-fill-seal technology, an advanced aseptic manufacturing process that forms, fills, and seals plastic containers in a continuous automated operation, ensuring high levels of sterility and product integrity. Unither's expertise encompasses the development and manufacturing of various liquid dosage forms including oral solutions, suspensions, nasal sprays, eye drops, and other sterile and non-sterile pharmaceutical products delivered in innovative single-dose formats. The company serves a diverse client base of pharmaceutical companies, biotechnology firms, and consumer health brands, providing comprehensive services from formulation development and clinical trial manufacturing to commercial-scale production and packaging. With manufacturing facilities strategically located across multiple continents including Europe and North America, Unither maintains strict quality standards and regulatory compliance with international pharmaceutical guidelines including FDA and EMA requirements. The company emphasizes innovation in drug delivery systems, patient convenience, and sustainability while helping clients bring their pharmaceutical products to market efficiently through its specialized manufacturing capabilities and technical expertise in unit-dose liquid formulations.
Company Leadership HH
JK
MC
MB
Founded in 1988 and headquartered in Westbury, New York, PL Developments is a manufacturer, packager, and distributor of pharmaceutical and consumer healthcare products.
Company Leadership
AN
CN
Alkermes plc is a global biopharmaceutical enterprise that specialises in developing and commercialising innovative medicines for people living with complex psychiatric and neurological disorders. Headquartered in Dublin, Ireland, the company combines deep neuroscience expertise with patient‑inspired science to pursue treatments for conditions such as addiction, schizophrenia, bipolar disorder, opioid dependence and other central nervous system diseases. Its approach integrates scientific research, clinical development and specialised commercial infrastructure to deliver both marketed medicines and investigational candidates, aiming to address serious unmet medical needs and improve how chronic neurological and mental health conditions are managed.
Company Leadership
SS
JS
Revolution Medicines Inc is a pioneering biotechnology company committed to revolutionizing treatment for patients battling cancer. They are driven by a singular mission: the discovery, development, and delivery of innovative, targeted medicines, particularly focusing on what are known as RAS-addicted cancers, which represent a significant proportion of new human cancer diagnoses. The company has developed a groundbreaking tri-complex inhibitor platform to create a portfolio of RAS(ON) inhibitors, enabling a differentiated approach to target what was previously considered an undruggable molecular target in oncology. Through their tireless efforts and commitment to transformative science, they are building a deep pipeline of therapeutic candidates intended to change the standard of care for patients with these challenging diseases.
Company Leadership AS
SK
Frequently Asked Questions Regarding Revance Therapeutics Top Executives and Leadership Team
